首页> 外国专利> VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF

VISTA REGULATORY T CELL MEDIATOR PROTEIN, VISTA BINDING AGENTS AND USE THEREOF

机译:Vista调节T细胞介质蛋白,Vista结合剂及其用途

摘要

The present invention relates to a novel regulatory T cell protein. This protein, designated PD-L3 OR VISTA resembles members of the PD-L1 family, identified a novel and structurally-distinct, Ig-superfamily inhibitory ligand, whose extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as PD-L3 OR VISTA or V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Expression of VISTA is primarily within the hematopoietic compartment and is highly regulated on myeloid APCs and T cells. Therapeutic intervention of the VISTA inhibitory pathway represents a novel approach to modulate T cell-mediated immunity for the treatment of a wide variety of cancers, e.g., ovarian, bladder cancer and melanomas. Also, VISTA proteins, especially multimeric VISTA proteins and antibodies may be used to suppress T cell immunity in autoimmune disease, allergy, infection and inflammatory conditions, e.g. multiple sclerosis and artritic conditions such as RA.
机译:本发明涉及一种新型调节性T细胞蛋白。该蛋白质,指定的PD-L3或Vista类似于PD-L1系列的构件,鉴定了一种新颖的和结构上明显的IG-Superfamily抑制配体,其细胞外结构域对B7家族配体PD-L1具有同源性。该分子被指定为T细胞活化(Vista)的PD-L3或VISTA或V域免疫球蛋白抑制剂。 Vista的表达主要在造血室内,在骨髓APC和T细胞上高度调节。 Vista抑制途径的治疗介入代表了一种调节T细胞介导的免疫力的新方法,用于治疗各种癌症,例如卵巢癌,膀胱癌和黑素瘤。此外,Vista蛋白质,特别是多聚体Vista蛋白和抗体可用于抑制自身免疫疾病,过敏,感染和炎症条件下的T细胞免疫力,例如,多发性硬化和竞争条件,如RA。

著录项

  • 公开/公告号US2021139578A1

    专利类型

  • 公开/公告日2021-05-13

    原文格式PDF

  • 申请/专利权人 THE TRUSTEES OF DARTMOUTH COLLEGE;

    申请/专利号US202017023927

  • 发明设计人 RANDOLPH J. NOELLE;LILI WANG;

    申请日2020-09-17

  • 分类号C07K16/28;C07K14/705;

  • 国家 US

  • 入库时间 2022-08-24 18:40:50

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号